Evidence map›Paper›PMID 33628051›Full record

ArticleCancer management and research2021

High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China.

Xuemei Xing, Zhigang Fan, Yue Gao, Zheng Liu

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xuemei Xing *Department of Clinical Laboratory, 3201 Hospital, Xi'an Jiaotong University Health Science Center, Hanzhong, Shaanxi, 723000, People's Republic of China.
Zhigang Fan *Department of Oncology, 3201 Hospital, Xi'an Jiaotong University Health Science Center, Hanzhong, Shaanxi, 723000, People's Republic of China.
Yue GaoCollege of Medical Laboratory Science, Guilin Medical University, Guilin, Guangxi, 541004, People's Republic of China.
Zheng LiuDepartment of Clinical Laboratory, 3201 Hospital, Xi'an Jiaotong University Health Science Center, Hanzhong, Shaanxi, 723000, People's Republic of China.
Guilin Medical University · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDescribing the clinical features of patients with breast cancer in an area is important to provide the information for the local oncologist to make sound treatment plans. In this study, we explored the clinical features of breast cancer patients in Southern Shaanxi Province, China. PATIENTS AND

methodsA total of 328 breast cancer patients between 2010 and 2015 were recruited at our hospital. Patients' clinical information and the results of the histopathological examination were collected. Independent sample

resultsThe peak age onset of these patients was between 45 and 50. At diagnosis, 8.23% of patients were at clinical stage 1 and 29.57% were triple-negative breast cancer subtype. High expression of Ki-67 in these patients was found associated with triple-negative breast cancer. The 5-year survival rate in these patients was 66.4%, and the survival rate in stage 1 and 2 patients (88.2%) was significantly higher than that in stage 3 and4 (57.4%).

conclusionWe here reported the clinical features of patients with breast cancer in Southern Shaanxi Province, China. The breast cancer patients in Southern Shaanxi Province showed a unique clinical feature.

Indexed as

5-year survival ratebreast cancerclinical featurestriple-negative breast cancer

Identifiers

PMID33628051
PMCPMC7898196
OpenAlexW3133479314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.